Efficacy and Safety of Gabapentin in the Treatment of Chronic Cough: A Systematic Review.
- Author:
Guanglin SHI
1
;
Qin SHEN
;
Caixin ZHANG
;
Jun MA
;
Anaz MOHAMMED
;
Huan ZHAO
Author Information
- Publication Type:Randomized Controlled Trial ; Review
- Keywords: Gabapentin; Cough; Treatment; Review Literature as Topic; Safety
- MeSH: Cough*; Humans; Prospective Studies; Quality of Life; Retrospective Studies; Review Literature as Topic
- From:Tuberculosis and Respiratory Diseases 2018;81(3):167-174
- CountryRepublic of Korea
- Language:English
- Abstract: Despite recent clinical guidelines, the optimal therapeutic strategy for the management of refractory chronic cough is still a challenge. The present systematic review was designed to assess the evidence for efficacy and safety of gabapentin in the treatment of chronic cough. A systematic search of PubMed, Embase, Cochrane Library databases, and publications cited in bibliographies was performed. Articles were searched by two reviewers with a priori criteria for study selection. Seven relevant articles were identified, including two randomized controlled trials, one prospective case-series designed with consecutive patients, one retrospective case series of consecutive patients, one retrospective case series with unknown consecutive status, and two case reports comprising six and two patients, respectively. Improvements were detected in cough-specific quality of life (Leicester Cough Questionnaire score) and cough severity (visual analogue scale score) following gabapentin treatment in randomized controlled trials. The results of prospective case-series showed that the rate of overall improvement of cough and sensory neuropathy with gabapentin was 68%. Gabapentin treatment of patients with chronic cough showed superior efficacy and a good safety record compared with placebo or standard medications. Additional randomized and controlled trials are needed.
